Macquarie cuts its price target on CSL shares. Is it still a buy?
Image source: Getty Images
CSL Ltd (ASX: CSL) shares have underperformed market expectations in recent times.
CSL shares have fallen 22% for the year to date.
Following its FY25 result, the healthcare giant fell 17%, marking its largest single-day decline since it listed in 1994.
A major focus of that earnings result was CSL’s plan to demerge vaccine business Seqirus, which surprised the market.
In the aftermath, a number of experts suggested the company had been oversold and assigned price targets well above the share price.
Since hitting its 52-week low of $189 in September, the company has rebounded around 15%.
While the S&P/ASX 200 Index (ASX: XJO) sits not too far below its all-time high, experts continue to see value in…
